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Previewsnecroptosis might influence this aspect of
the hyperinflammatory shock, Duprez
et al. monitored the plasma concentra-
tions of IL-1 and IL-6 upon systemic TNF
administration. Unexpectedly, both WT
and Ripk3/ mice (as well as mice that
had been pretreated with Nec-1) ex-
hibited an early (2 hr after TNF injection)
increase in circulating IL-1 and IL-6.
However, whereas inWTmice the plasma
concentrations of IL-1 and IL-6 nearly
doubled 4 hr later (that is 6 hr after the
administration of TNF), in Ripk3/ (as
well as in Nec-1-pretreated) animals they
regressed to near-to-baseline amounts
(Duprez et al., 2011). Thus, necroptosis-
proficient and -deficient mice did not
differ from each other relative to the early
wave of cytokine secretion that is
believed to be a direct consequence of
the administration of TNF. Still, they
behaved in a markedly distinct fashion
with respect to the delayed production
of proinflammatory modulators, which
the authors hypothesize to be stimulated
by circulating DAMPs. Although this latter
point remains to be formally demon-
strated, the results by Duprez et al. argue
against a causal role for the early wave of
cytokine release in the development of
SIRS, in turn casting some doubts on
the actual contribution of the cytokinestorm to shock-associated mortality in
clinical settings.
The discovery that necrosis does not
constitute a merely accidental cell death
mode but also can occur in a finely regu-
lated fashion has generated great clinical
and therapeutic expectations. On one
hand, anticancer therapies that trigger
the necrotic death of tumor cells may be
particularly suitable for the eradication of
apoptosis-resistant malignancies. On the
other hand, avoiding the unwarranted
necrotic demise of postmitotic cells may
turn out to be beneficial in an ever-
growing list of clinically relevant condi-
tions in which regulated necrosis is in-
volved as a causal determinant. This list
now includes hyperinflammatory shock
and hypoinflammatory sepsis. Although
the underlying molecular and cellular
mechanisms, in particular the link(s)
between circulating DAMPs and the
delayed wave of cytokine release, have
not been precisely elucidated, the
work by Duprez et al. suggests that
necroptosis-targeting agents may consti-
tute a valuable alternative to anti-inflam-
matory therapies and cytokine blockers
for the treatment of shock. Future will
tell whether these compounds will make
all their way from the bench to the
bedside.Immunity 35, DREFERENCES
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Plasmacytoid dendritic cells (pDCs) have potential influence on innate and adaptive immune responses. In
this issue of Immunity, Takagi et al. (2011) established mice lacking pDCs and explored the impact of pDC
ablation in vivo.Plasmacytoid dendritic cells (pDCs), also
known as type I interferon-producing cells
(IPCs), are specialized cells of the immune
system that rapidly secrete massive
amounts of type I interferon after activa-tion via Toll-like receptor 7 (TLR7) and/or
TLR9 by sensing pathogenic nucleic
acids. Subsequent to type I IFN produc-
tion, activated pDCs differentiate into
a unique type of mature DC and acquirethe ability to activate T cells (Liu, 2005).
Previous studies show that regardless of
their maturation stage and activation
signals, pDCs have an intrinsic ability to
prime naive T cells to differentiate intoecember 23, 2011 ª2011 Elsevier Inc. 851
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Figure 1. The Multiple Roles of pDCs in Immune Responses In Vivo
Plasmacytoid dendritic cells (pDCs) secrete massive amounts of type I IFNs after activation with viral or
bacterial nucleic acids via TLR7 and/or TLR9. Type I IFNs are key cytokines that link innate and adaptive
immune responses during viral or bacterial infection. The pDC-ablated mouse model presented in Takagi
et al. definitively demonstrates the following in vivo roles of pDCs: (1) TLR9-mediated inflammation: pDCs
were shown to initiate TLR-mediated inflammation triggered by CpG-A; (2) regulation of adaptive
immunity: pDCs were shown to control antigen-specific CD4+ T cells responses by generating
CD4+Foxp3+ Treg cells and to induce differentiation of CD8+ T cells after exposure to exogenous antigens;
(3) mucosal tolerance: pDCs maintained mucosal tolerance by generating CD4+Foxp3+ Treg cells;
(4) bacterial immunity: pDCs induced bacterial septic shock and further exacerbate bacteria infection
by impairing bacterial clearance; and (5) viral immunity: pDCs controlled viral infection by producing
type I IFNs and by supporting antiviral CD8+ T cell differentiation. Dysregulation of these pDC functions
could cause the pathogenesis of infectious disease, autoimmune disease, asthma and cancer.
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Previewsinterleukin-10 (IL-10)-producing T cells in
both humans and mice. Results of recent
studies also indicate that pDCs may
indeed play a critical role in T cell toler-
ance including mucosal tolerance in the
airway, gut, and liver, graft transplanta-
tion, and tumor microenvironment, which
is mostly associated with the induction
of regulatory T cells (Liu, 2005). Thus,
these studies suggest that pDCs, either
at a resting or mature stage, may act as
a regulatory DC when directly presenting
antigens to naive T cells and that pDCs
may mainly trigger productive T cell
immune responses through the activation
of conventional DCs (cDCs) and other
cells in vivo. Although the various roles
of pDCs have been extensively studied
in vitro and ex vivo, the precise role of
pDCs in vivo has remained unknown.
One approach used frequently to deter-
mine the function of pDCs in vivo is to
eliminate pDCs by using monoclonal anti-
bodies that recognize surface molecules
expressed on pDCs, such as Gr-1 and
BST-2 (Swiecki and Colonna, 2010).
However, both Gr-1 and BST-2 are not
specific to pDCs and are constitutively
expressed by other immune cells or are
induced on many cell types after activa-
tion. It is therefore highly likely that these
antibodies may result in the depletion of852 Immunity 35, December 23, 2011 ª2011additional cell types or modulate their
function in vivo.
In this issue of Immunity, Takagi et al.
(2011) have successfully established
a DTR-based mice targeting the sialic
acid binding Ig-like lectin (Siglec)-H
gene, which allowed them to investigate
the contribution of pDCs during the
immune response in a variety of experi-
mental animal models by inducing selec-
tive elimination of pDCs (Figure 1).
Although CD209b+ marginal zone macro-
phages also express intracellular Siglec-
H (Zhang et al., 2006), administration
of DT into Siglech-DTR mice selectively
eliminated pDCs but not CD209b+
marginal zone macrophages. Because
pDCs from Siglech-DTR mice have
a defect in Siglec-H expression at the
translational level, Siglech-DTR mice
also permitted them to evaluate the
function of Siglec-H-deficient pDCs as
well as the specific ablation of pDCs
in vivo.
Siglec-H, which is predominantly ex-
pressed on pDCs in mice, is a member
of the sialic-acid-binding immunoglobin
(Ig)-like lectin (Siglec) family that signals
through the adaptor protein DAP12
(Blasius et al., 2006). Although the ligand
of Siglec-H is still unknown, crosslinking
of Siglec-H with specific antibodies abol-Elsevier Inc.ishes IFN-a production induced by TLR9
ligands (Blasius et al., 2006). Takagi
et al. confirmed previous reports showing
that Siglec-H-deficient pDCs in culture
have increased production of IFN-a and
IL-12p40 after activation with CpG-A
through increased activation of the
NF-kB, IkBa, and IKK-a-mediated sig-
naling cascade, suggesting an inhibitory
function of Siglec-H in pDCs.
Because TLR7 and TLR9 are expressed
by several immune cell types in mice,
the direct contribution of pDCs to
TLR-mediated inflammatory responses
in vivo has yet been defined. The authors
employed the lethal shock mouse model
system triggered by CpG-A with D-galac-
tosamine (D-GalN) to investigate this
issue. Administration of CpG-A elicited
a substantial increase of type I IFNs and
proinflammatory cytokines in Siglec-H–
deficient mice compared to wild-type
mice. In contrast, pDC-ablated mice
exhibited a dramatic reduction in these
cytokines, which correlated with the high
survival rate of these mice. These results
strongly support the notion that pDCs
are key players in the initiation of TLR9-
mediated inflammation and that Siglec-H
controls the amplitude of pDC respon-
siveness by interacting with a putative
physiological ligand in vivo.
The authors further explored the influ-
ence of pDC deletion in antigen-specific
CD4+ and CD8+ T cell priming under
steady state and inflammatory conditions.
They demonstrated that pDCs promoted
the induction of peripheral tolerance by
generating antigen-specific CD4+Foxp3+
Treg cells and consequently dampened
the differentiation of antigen-specific
CD4+ effector T cells induced by other
DCs under both steady state and inflam-
matory conditions in vivo. The authors
also showed that pDCs were involved in
the homeostasis of CD4+Foxp3+ Treg
cells in the lamina propria (LP) in the small
intestine but not in the periphery. Impor-
tantly, CD4+Foxp3+ Treg cells generated
by pDCs in the LP played a crucial role
in controlling the differentiation of inflam-
matory T cells (T helper 1 [Th1] and Th17
cells), which is important for maintaining
immune equilibrium in mucosal tissue.
Finally pDCswere shown to have a poten-
tial capacity to cross-present exogenous
antigen to activate CD8+ T cells in vivo
and Siglec-H was shown to be involved
in this process.
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PreviewsIn vivo deletion of pDCs with Siglech-
DTR mice also allowed the authors to
examine the impact of pDCs on both
bacterial and viral infection. Their experi-
ments demonstrated that pDCs partici-
pated in septic shock by producing
massive amounts of proinflammatory
cytokines. Interestingly, pDC-ablated
mice showed better bacterial clearance
than wild-type mice, which was accom-
panied by a high retention of cDCs. These
results suggest the harmful aspects of
pDCs that could impair bacterial clear-
ance mediated by antibacterial CD8+
T cells induced by cDCs in vivo. They
further demonstrated that during HSV-1
infection, pDCs were a major source of
type I IFNs but not IL-12p40. In addition,
pDCs played a critical role in the genera-
tion of anti-HSV-1 CD8+ T cells.
It is key to establish a mouse system
lacking pDCs for further understanding
of the true physiological role of pDCs.
Thus, the Siglec-H DTR mice established
by Takagi’s group will be a promising
and powerful tool to unravel the function
of pDCs in vivo. In the series of experi-
ments reported here, Takagi et al. (2011)
confirmed several fundamental functions
of pDCs as proposed by previous studies
and further revealed some unique as-
pects of pDC biology (Figure 1). For
example, it is an important question
whether the engagement of Siglec-H
by its natural ligand(s) induces an inhibi-
tory effect in pDC function in vivo, as
shown by crosslinking with antibody
in vitro. SiglecH-deficient mice allowed
the authors to definitively demonstrate
that Siglec-H negatively regulates pDC
responsiveness to produce type I IFNs in
response to a TLR ligand by interacting
with its physiological putative ligand(s)
in vivo. It will be important to identify the
natural ligand(s) of Siglec-H for further
understanding of its precise roles in pDC
biology.
There has been some controversy
regarding the ability of pDCs to elicit
productive antigen-specific T cell re-
sponses from naive T cells in vivo
because of their lower capacity to prime
T cells compared to cDCs. The authors’
studies clearly demonstrated the impor-
tance of pDCs in the regulation of T cell
immune responses by generating regula-
tory T cells. Thus, the main role of pDCs
as antigen-presenting cells (APCs) in vivo
may be to act as regulatory DCs to controlimmune responses and maintain mucosal
immune tolerance.
Another interesting finding is the harm-
ful aspects of pDCs during bacterial
clearance. In contrast to proinflammatory
cytokines (IL-6 and TNF-a), type I IFNs
have been known as ‘‘beneficial’’ cyto-
kines for bacterial growth (Auerbuch
et al., 2004; Carrero et al., 2004; O’Con-
nell et al., 2004). Mice with elevated type
I IFNs have a greater bacterial burden.
Thus, it was speculated that Listeria
monocytogenes (LM) might induce type I
IFNs to their benefit in order to impair
the immune response that played an
important role in controlling bacterial
clearance. The author’s study using
pDC-ablated mice demonstrated that
pDCs impaired bacterial clearance
possibly by affecting the survival of
cDCs that were crucial for the generation
of anti-Listeria CD8+ T cells to eliminate
bacteria. Dysregulated inflammation
induced a systemic loss of cDCs during
bacterial sepsis (Efron et al., 2004; Takagi
et al., 2011). Thus, excessive production
of type I IFNs by pDCs during early
massive bacterial infection may account
for the detrimental effect of pDCs. Inter-
estingly, the inhibition of cytokine produc-
tion by Siglec-H was not observed during
bacterial infection, which was in contrast
to cytokine expression after CpG-A inoc-
ulation or HSV-1 infection. Although it
has to be considered carefully whether
the function of Siglec-H expressing
marginal zonemacrophages ismodulated
in Siglec-H DTR mice, these findings may
provide some clues to elucidate the
physiological function of Siglec-H and
the etiology of internal bacterial infection.
Details of the molecular mechanisms,
including the contribution of type I IFNs,
have to be examined.
pDCs have been implicated to play an
important regulatory role in asthma, auto-
immune disease, and cancer as well as
viral infection (Figure 1). Because pDCs
produce robust amounts of type I IFNs in
response to nearly all viruses in vitro,
they are expected to play a crucial role
in antiviral immune responses in vivo.
However, previous studies using de-
pleting antibodies demonstrated that
pDCs were dispensable in the control of
certain kinds of viral infections (Swiecki
and Colonna, 2010). Accumulated evi-
dence also reveals that chronic activation
of pDCs and unregulated secretion ofImmunity 35, Dtype I IFNs result in autoimmune diseases
such as SLE, psoriasis vulgaris, EAE, and
type 1 diabetes in NOD mice (Gilliet et al.,
2008). However, studies of pDC-depleted
mice using antibody have given conflict-
ing results. This may be explained by the
following: First, because pDCs are such
potent inducers of type I IFN, any partial
depletion of pDCs would probably not
be sufficient to diminish their effects,
and type I IFNs produced by a few re-
maining pDCs may obscure the real
phenotype of pDC-ablated mice; second,
because Ly-6C and BST-2 are not really
specific to pDCs, antibodies against
these molecules may result in the deple-
tion of additional cell types during immune
responses. The inducible short-term abla-
tion of pDCs in Siglech-DTR mice may
limit their use in long-term experiments,
such as the chronic viral infection and
autoimmune disease. Yet, it is important
to further explore the animal models with
conditional ablation of pDCs in Siglech-
DTR mice. This animal system will prob-
ably change our over view of pDC biology
and holds future promise for the develop-
ment of better therapeutic agents for
infectious disease, autoimmune disease,
cancer, allergy, and asthma.
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